AxoGen (AXGN) Stock Forecast, Price & News

AxoGen (NASDAQ:AXGN) Frequently Asked Questions

Is AxoGen a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AxoGen stock.
View analyst ratings for AxoGen or view top-rated stocks.

When is AxoGen's next earnings date?

AxoGen is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for AxoGen.

How were AxoGen's earnings last quarter?

AxoGen, Inc. (NASDAQ:AXGN) released its quarterly earnings data on Wednesday, May, 4th. The medical equipment provider reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by $0.03. The medical equipment provider earned $31.01 million during the quarter, compared to analyst estimates of $30.40 million. AxoGen had a negative net margin of 24.98% and a negative trailing twelve-month return on equity of 26.64%. During the same quarter in the previous year, the business earned ($0.15) earnings per share.
View AxoGen's earnings history.

What guidance has AxoGen issued on next quarter's earnings?

AxoGen updated its FY 2022 earnings guidance on Monday, May, 16th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $135.00 million-$142.00 million, compared to the consensus revenue estimate of $137.94 million.

What price target have analysts set for AXGN?

4 brokerages have issued 1-year price targets for AxoGen's shares. Their forecasts range from $15.00 to $27.00. On average, they expect AxoGen's share price to reach $19.25 in the next year. This suggests a possible upside of 98.0% from the stock's current price.
View analysts' price targets for AxoGen or view top-rated stocks among Wall Street analysts.

Who are AxoGen's key executives?

AxoGen's management team includes the following people:

• Ms. Karen Zaderej, Chairman, Pres & CEO (Age 60, Pay $1.16M) (LinkedIn Profile)
• Mr. Peter J. Mariani, Exec. VP & CFO (Age 58, Pay $696.4k)
• Ms. Maria D. Martinez, Chief HR Officer (Age 54, Pay $498.62k) (LinkedIn Profile)
• Mr. Angelo G. Scopelianos Ph.D., Chief R&D Officer (Age 67, Pay $613.99k)
• Mr. Eric A. Sandberg, Chief Commercial Officer (Age 57, Pay $529k)
• Mr. Michael Donovan, VP of Operations (Age 57)
• Ed Joyce, Director of Investor Relations
• Mr. Bradley L. Ottinger J.D., Gen. Counsel & Chief Compliance Officer (Age 52)
• Mr. Gregory Davault, VP of Marketing (Age 54)
• Ms. Isabelle Billet, Chief Strategy & Bus. Devel. Officer (Age 60)

What is Karen Zaderej's approval rating as AxoGen's CEO?

3 employees have rated AxoGen CEO Karen Zaderej on Glassdoor.com. Karen Zaderej has an approval rating of 100% among AxoGen's employees. This puts Karen Zaderej in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of AxoGen's key competitors?

Some companies that are related to AxoGen include Natus Medical (NTUS), Outset Medical (OM), Cutera (CUTR), TransMedics Group (TMDX), BioLife Solutions (BLFS), ViewRay (VRAY), Zynex (ZYXI), Edap Tms (EDAP), Semler Scientific (SMLR), Hyperfine (HYPR), Stereotaxis (STXS), FONAR (FONR), Electromed (ELMD), Electromed (ELMD) and Second Sight Medical Products (EYES).
View all of AXGN's competitors.

What other stocks do shareholders of AxoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Advanced Micro Devices (AMD), Bank of America (BAC), Intelsat (I), Intel (INTC), Micron Technology (MU), Xilinx (XLNX), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), NVIDIA (NVDA) and Fossil Group (FOSL).

What is AxoGen's stock symbol?

AxoGen trades on the NASDAQ under the ticker symbol "AXGN."

Who are AxoGen's major shareholders?

AxoGen's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.18%), First Light Asset Management LLC (5.77%), Vanguard Group Inc. (4.58%), William Blair Investment Management LLC (3.88%), State Street Corp (2.57%) and Assenagon Asset Management S.A. (1.64%). Company insiders that own AxoGen stock include Angelo Scopelianos, Erick Wayne Devinney, Gregory Gene Freitag, Isabelle Billet, Karen L Zaderej, Karen L Zaderej, Maria D Martinez, Michael Patrick Donovan and Peter J Mariani.
View institutional ownership trends for AxoGen.

Which institutional investors are selling AxoGen stock?

AXGN stock was sold by a variety of institutional investors in the last quarter, including Parkman Healthcare Partners LLC, Exchange Traded Concepts LLC, Skandinaviska Enskilda Banken AB publ , Dimensional Fund Advisors LP, UBS Group AG, Goldman Sachs Group Inc., Northern Trust Corp, and Engineers Gate Manager LP. Company insiders that have sold AxoGen company stock in the last year include Karen L Zaderej, Maria D Martinez, and Michael Patrick Donovan.
View insider buying and selling activity for AxoGen or view top insider-selling stocks.

Which institutional investors are buying AxoGen stock?

AXGN stock was purchased by a variety of institutional investors in the last quarter, including SCW Capital Management LP, Assenagon Asset Management S.A., CI Investments Inc., Friess Associates LLC, First Light Asset Management LLC, Renaissance Technologies LLC, Vanguard Group Inc., and William Blair Investment Management LLC.
View insider buying and selling activity for AxoGen or or view top insider-buying stocks.

How do I buy shares of AxoGen?

Shares of AXGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AxoGen's stock price today?

One share of AXGN stock can currently be purchased for approximately $9.72.

How much money does AxoGen make?

AxoGen has a market capitalization of $408.06 million and generates $127.36 million in revenue each year. The medical equipment provider earns $-26.99 million in net income (profit) each year or ($0.76) on an earnings per share basis.

How many employees does AxoGen have?

AxoGen employs 428 workers across the globe.

What is AxoGen's official website?

The official website for AxoGen is www.axogeninc.com.

How can I contact AxoGen?

AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The medical equipment provider can be reached via phone at (386) 462-6800, via email at [email protected], or via fax at 386-462-6801.